United States Defends Falsity Theory, Use of Debatable Sub-Regulatory Guidance in Medicare Advantage False Claims Act Suit Against Kaiser Permanente
- September 16, 2022
- John Kelly , Barnes & Thornburg LLP
- Jackie Papish , Barnes & Thornburg LLP
- A.J. Bolan , Barnes & Thornburg LLP
![Scales and gavel](/getmedia/54695074-a0fc-4740-a1a5-8b7b8960286d/Image_900x500_SCALES2_20_SIZEABLE.jpg?width=900&height=500&ext=.jpg)
The False Claims Act actions pending against the Kaiser Permanente Consortium members in the U.S. District Court for the Northern District of California concerning Kaiser’s Medicare Advantage risk-adjustment practices are teeing up a possible showdown regarding what constitutes sub-regulatory guidance and when sub-regulatory guidance can support a legal falsity claim.
ARTICLE TAGS
You must be logged in to access this content.